R&D
Technology to Increase Selectivity for
cancer cells and Enhance Efficacy
PINOT-ADC™
  • HOME
  • R&D
  • PINOT-ADC™

Next Generation ADC Platform

PINOT-ADC™ is a next-generation ADC anticancer drug platform technology that uses an independent drug (Payload) and linker that overcome the limitations of existing ADC drugs.
Based on the PINOT-ADC™ technology, we are jointly conducting research and development of a number of candidate substances such as the best-in-class ADC anticancer drug (PBX-001) targeting solid cancer Trop2 with various partner companies.

Distinction and Competitive Advantage

Topoisomerase 1 inhibitor payload

On top of Top1 inhibition, the payload can also suppress anti-apoptotic protein expression and induce innate immune response to exert a powerful anti-cancer efficacy

Bystander effect is optimized via cell membrane permeability

Highly safe with minimal side effects or toxicity in the normal tissue

Resistance can be overcome by evading ABCG2, a protein which acts as drug efflux pump

Cleavable linker(Acid/Enzyme)

Highly scalable and can be customized according to each target’s property

Rapid activation and drug release in the tumor cells

High hydrophilicity minimizes absorption into normal tissue

Specific to a given target

Joint research with both domestic and global antibody developers

Platform is applicable across wide-range of drug delivery modality, such as aptamer, repebody, etc.

PINOT-ADC™ Platform



PINOT-ADC™ MOA Animation



Clinical trial status

Project/Target Indication Development Stage

Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Antibody
Provider
Licensee
ADC
platform
Pipeline
PBX-CT01
(Undisclosed)
Undisclosed
ADC
Products
Pipeline
PBX-001
(Trop2)
Triple Negative Breast Cancer (TNBC), lung cancer, bladder cancer, etc.
Sacituzumab
Biosimilar
-
PBX-002
(Undisclosed)
Triple Negative
Breast Cancer (TNBC), etc.
Undisclosed -
PBX-003
(EGFR)
Colorectal cancer,
lung cancer,
head and neck cancer, etc.
-